Publications
- Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment2018 | Faculty of Pharmacy in Hradec Králové
- Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase2014 | Faculty of Pharmacy in Hradec Králové
- Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo2023 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study2022 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter2022 | Faculty of Pharmacy in Hradec Králové
- Substituted N-phenylitaconamides as inhibitors of mycobacteria and mycobacterial isocitrate lyase2022 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Faculty of Pharmacy in Hradec Králové
- Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
Loading network view...